17 results about "Cervical carcinoma" patented technology

The invention belongs to the technical field of gene methylation detection, and particularly relates to a cervical cancer related gene methylation detection kit and system, which comprises primers and probes for detecting APC, CALCA, DAPK and ESR1 gene methylation, primers and probes for monitoring internal control genes, a PCR reaction liquid, a positive quality control product and a negative quality control product, the use method comprises the following steps: 1) performing nucleic acid extraction on a sample; (2) converting the extracted genome DNA by bisulfite; (3) premixing and subpackaging the gene methylation detection reagent to obtain a PCR reaction system; (4) adding the DNA obtained in the step (2) into the PCR reaction system in the step (3), uniformly mixing, and carrying out PCR amplification; 5, gene methylation interpretation is carried out after the reaction is ended, the method has the advantages of being high in sensitivity, low in cost, easy and convenient to operate, short in detection period, visual in interpretation and the like, and methylation of the cervical cancer related genes can be rapidly and accurately detected.

The invention discloses a kit for predicting the treatment effect of a combined drug composition for cervical cancer, which predicts the treatment effect of a'VEGFR inhibitor + PD-1 monoclonal antibody 'combined scheme by detecting serum arginine or SLC6A14 expression quantity in cervical cancer tissues, can help patients to select the treatment scheme in a more targeted manner, can improve the effectiveness of drug use, and has the advantages of simple operation, low cost and high efficiency. And poor prognosis or treatment opportunity delay caused by selection of treatment schemes is avoided, and the method has a good application prospect.

The application discloses a series of derivatives based on natural product gelsemium methyl, pharmaceutically acceptable salts and preparation methods thereof. Bioactivity tests show that the compounds have the effect of inhibiting the proliferation of various tumor cells. The compounds can be used for the treatment of various cancers (including but not limited to gastric cancer, liver cancer, lung cancer, esophageal cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, nasopharyngeal cancer, ovarian cancer, kidney cancer, bladder cancer, thyroid cancer and skin cancer) as active pharmaceutical ingredients.

Small molecule ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells are disclosed. In one embodiment, the small molecule biomodulator has increased therapeutic utility because of an increased ability to kill therapy-resistant cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen, and fulvestrant / ICI). The small molecule biomodulators not only inhibit proliferation of the cancer cells but kills them, which prevents reactivation of tumors years later. Compounds of the invention, such as ErSO-TFPy, are effective for treating ERα positive cancers such as breast cancer, ovarian cancer, uterine cancer, cervical carcinoma, endometrial cancer, and the like.

The application discloses a butyl tin-cycloiridium phenanthroline complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anticancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, a phenyl group, a p-tolyl group, a p-bromophenyl group, a p-fluorophenyl group, a biphenyl group, a triphenylamine group, a carbazole group, a tetraphenyl ethene group and a triphenylbenzene group. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target compound shows potential anticancer activity. In addition, the target compound shows unique AIE emission characteristics. The target compound mainly targets the lysosomes of A549 cells, and influences the mitochondria to cause the decline of the mitochondrial membrane potential, thereby showing anticancer activity.

The invention belongs to the technical field of gene detection, and discloses application of EVX2 gene methylation in evaluation of cervical carcinoma risk of high-risk HPV infected persons. The biomarker for evaluating the cervical cancer risk of the high-risk HPV infected person is a methylation site of an EVX2 gene. According to the invention, detection of the methylation level of the EVX2 gene is applied to evaluation of cervical cancer risk of high-risk HPV infected people, and the kit can be used for screening and shunting cervical HSIL and cervical cancer and is beneficial to early intervention of high-risk HPV infected people.

Disclosed herein are antibody drug complexes comprising a drug unit coupled to an antibody capable of binding to TROP2 or an antigen-binding fragment thereof, and methods of using the antibody drug complexes. The methods of use include, but are not limited to, cancer treatment and detection. The antibody drug complexes disclosed herein can bind to specific cancer cell surfaces. Exemplary targets of the antibody drug complexes disclosed herein include epithelial cancers, such as lung cancer, breast cancer, head and neck cancer, esophageal cancer, gastric cancer, bladder cancer, pancreatic cancer, colorectal cancer, cervical cancer, endometrial cancer, ovarian cancer, laryngeal cancer, prostate cancer, thyroid cancer, and oral cancer.

The present disclosure relates to methods, combinations and uses for the treatment of cervical cancer using an anti-PD-L1 binding protein or an anti-PD-1 binding protein and chemoradiotherapy.

The utility model relates to a condom device worn on a mouth, a lip and a tongue, which is an integrally formed long sheet type high-density elastic film body and can be hung on the mouth, the lip and the tongue, two side edges extend to the back of the back of the head and the neck, and two sides of two ends are respectively provided with a hole of a hook buckle so as to hook the long sheet type high-density elastic film body of the condom. The front mouth, lip and tongue position of the long sheet type high-density elastic film body is designed to be of a protruding three-dimensional bag-shaped space structure, the tongue can stretch out of the protruding three-dimensional bag-shaped space structure and can flexibly move up, down, left and right and suck and lick, and the surface layer is provided with protruding three-dimensional small-particle lines and concave-convex lines besides the smooth surface, so that the mouth, the lip and the tongue of the long sheet type high-density elastic film body is not prone to falling off. When the device is used in the relation, direct contact of body fluid and secretions of sexual objects can be blocked, infection of various venereal diseases and invasion of human mastoid HPV viruses are avoided, diseases, oral esophageal cancer and cervical cancer are prevented, and safe life is created.

The invention discloses a prognosis model for predicting cervical cancer based on autophagy-related genes and a construction method of the prognosis model, and belongs to the technical field of biomedicine. The model contains four characteristic genes related to prognosis of cervical cancer: BCL2, SPNS1, TM9SF1 and TP73, and the characteristic genes can become biological markers related to cervical cancer; the calculation formula of the prognosis model is as follows: risk score = (-0.411 * BCL2 gene expression quantity) + (0.753 * SPNS1 gene expression quantity) + (0.669 * TM9SF1 gene expression quantity) + (-0.398 * TP73 gene expression quantity). The prognosis model provided by the invention can evaluate the prognosis of the cervical cancer patient, improve the prognosis prediction capability of the cervical cancer patient, effectively identify the high-risk patient, assist in predicting the curative effect of immunotherapy, detect and intervene the high-risk patient earlier in clinic, improve the survival rate and life quality of the patient, and improve the clinical application prospect. A reference is provided for individualized diagnosis and treatment of cervical cancer; and tests and external verification prove that the model is stable and effective.

The present application relates to the technical field of drug synthesis, in particular to a benzylurea compound, a preparation method and application thereof. The structural formula of the benzylurea compound is shown in the following: wherein R1 represents any one of a connecting bond, a substituted or unsubstituted amide bond and a C1-C10 unsubstituted alkyl bond, and R2 is selected from any one of a substituted or unsubstituted single aromatic heterocyclic group, or a substituted or unsubstituted single aromatic ring group, or a substituted or unsubstituted benzo-fused ring group. The benzylurea compound can effectively inhibit the activity of tumor cells, and has a good therapeutic effect on esophageal cancer, lung cancer, gastric cancer, breast cancer, colorectal cancer, laryngeal cancer, nasopharyngeal cancer, oral cancer, pancreatic cancer, renal cancer, prostate cancer, bladder cancer, cervical cancer, lymphoma, acute leukemia, osteosarcoma, Ewing's sarcoma and thyroid cancer.

The invention relates to the technical field of cervical lesions, and discloses a cervical lesion risk prediction model based on combination of double gene methylation and clinical characteristics and application thereof, and the method comprises the following steps: S1, selecting a research object; s2, carrying out double-gene methylation detection; and S3, data statistical analysis: performing statistical analysis by applying SPSS 25.0 and R4.1. 2 software, performing chi-square test and single-factor logistic regression analysis on each potential influence factor, and bringing the screened influence factors into multi-factor logistic regression analysis. According to the cervical lesion risk prediction model based on combination of double-gene methylation and clinical characteristics and application and development thereof, evidence-based basis can be better provided, clinical reduction of missed diagnosis and misdiagnosis rates of cervical cancer is helped, morbidity and mortality are reduced, and implementation of a strategic target of eliminating cervical cancer in China is assisted.

The invention belongs to the technical field of biomedicine, particularly relates to the field of molecular diagnosis, and more particularly relates to a kit for screening cervical canceration and application of the kit. The invention provides a biomarker for screening cervix canceration, the biomarker is at least one of an XIRP2 autoantibody, a POU3F2 autoantibody and a PCNA autoantibody, the expression level of the marker in serum of a patient with cervix canceration is obviously higher than that of a normal person, and the difference has statistical significance. The invention also provides a kit for screening cervical canceration. The kit contains an antigen for detecting the biomarker. By detecting the expression level of the biomarker in human serum, the biomarker can be used for screening and diagnosing cervical canceration.

This invention belongs to the field of chemical pharmaceuticals and synthesis technology, specifically relating to dihydropyrroloquinazoline spiroindole ketones, their applications, pharmaceutical compositions, and synthetic methods. The compounds provided by this invention exhibit inhibitory activity against the proliferation of HeLa and A-549 cancer cells, suggesting that these compounds could serve as active ingredients in anticancer drugs for cervical cancer, lung cancer, and other cancers. In particular, some compounds significantly inhibit the growth and proliferation of A-549, indicating the potential pharmaceutical value of these compounds and providing new structural units for drug screening. Furthermore, the synthetic method of this invention uses a one-pot synthesis of 1-(aryl)methylimine-substituted indoline compounds and 3-diazo-2-indole ketone compounds as starting materials. This synthetic method has advantages such as readily available and simple starting materials, easy operation, mild conditions, wide substrate applicability, and high atom economy.

The invention relates to the technical field of three-tube type arc-shaped after-loading source applicator, in particular to a three-tube type arc-shaped after-loading source applicator for cervical cancer eccentric tumors, which aims at solving the problems of fuzzy nuclear magnetic development and tube position fixation of plastic materials, and is characterized in that outer enclosures with spiral development tubes are arranged on the outer walls of a uterine cavity tube and a dome tube; the internal air cavity is used for inducing magnetic sensitive artifacts in the MRI to improve the visibility of the target region; a pure titanium developing ring is pre-buried in a conical sealing area at the pipe end, and dual-mode coordinate registration is achieved in combination with a CT highlight signal. The push plate is of a double-layer structure, the locking shaft mechanism fixes the position of the uterine cavity tube, the split frame slides through the distance adjusting groove to adjust the distance between the dome tubes, the threaded push tube controls the extension length, and the traction spring restrains deflection. Tungsten alloy foils are annularly arranged in the shielding groove to absorb backward radiation and assist the contact block to improve histocompatibility. According to the invention, the bottleneck of development and structure adjustment is broken through, and precise hardware support is provided for individualized radiotherapy.

The application discloses a butyl tin-cyclo iridium salicylaldehyde Schiff base complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anti-cancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, chlorine, bromine, methyl, methoxy and trifluoromethoxy. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cancer cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target complex shows potential anti-proliferation activity and is superior to cisplatin. In addition, the target compound shows unique AIE emission characteristics. The target compound can target the mitochondria of A549 cells and cause the decline of the mitochondrial membrane potential, thereby showing anti-cancer activity.

The present technology provides compounds, as well as compositions including such compounds, useful for imaging and / or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and / or a prostate cancer. The compounds are represented by the following formulaor a pharmaceutically acceptable salt thereof.